Somatic POLE proofreading domain mutation, immune response and prognosis in colorectal cancer: a retrospective, pooled biomarker study
Background<br/> Precision cancer medicine depends on defining distinct tumour subgroups using biomarkers that may occur at very modest frequencies. One such subgroup comprises patients with exceptionally mutated (ultramutated) cancers caused by mutations that impair DNA polymerase epsilon (POL...
Автори: | Domingo, E, Freeman-Mills, L, Rayner, E, Glaire, M, Briggs, S, Koelzer, V, Frangou, E, Dutton, P, Kerr, R, Kerr, D, Tomlinson, I, Church, D, EPICOLON consortium |
---|---|
Формат: | Journal article |
Опубліковано: |
Lancet
2016
|
Схожі ресурси
-
POLE proofreading domain mutation defines a subset of immunogenic colorectal cancers with excellent prognosis
за авторством: Glaire, MA, та інші
Опубліковано: (2016) -
POLE proofreading mutation, immune response and prognosis in endometrial cancer
за авторством: Van Gool, I, та інші
Опубліковано: (2015) -
POLE proofreading mutations elicit an anti-tumor immune response in endometrial cancer
за авторством: Klenerman, P, та інші
Опубліковано: (2015) -
Adjuvant treatment for POLE proofreading domain-mutant cancers: sensitivity to radiotherapy, chemotherapy, and nucleoside analogues
за авторством: Van Gool, I, та інші
Опубліковано: (2018) -
A panoply of errors: polymerase proofreading domain mutations in cancer
за авторством: Rayner, E, та інші
Опубліковано: (2016)